Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
23 studies found for:    Open Studies | "Granulomatosis with Polyangiitis"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Granulomatosis with Polyangiitis"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)
Conditions: Granulomatosis With Polyangiitis (Wegener's);   Granulomatosis With Polyangiitis;   Wegener's Granulomatosis;   ANCA-Associated Vasculitis
Interventions: Drug: Abatacept;   Drug: placebo
2 Recruiting Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis
Conditions: Granulomatosis With Polyangiitis;   Microscopic Polyangiitis;   Wegener's
3 Not yet recruiting Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
Condition: Granulomatosis With Polyangiitis (Wegener's Granulomatosis)
Interventions: Drug: Rituximab;   Other: Placebo
4 Recruiting Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis)
Condition: Granulomatosis With Polyangiitis
Interventions: Other: Blood samples and clinical data;   Other: Blood sample
5 Not yet recruiting Rituximab in Eosinophilic Granulomatosis With Polyangiitis
Condition: Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Interventions: Drug: Rituximab;   Drug: Placebo-rituximab;   Drug: Cyclophosphamide;   Drug: Placebo-cyclophosphamide
6 Recruiting A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
Condition: Granulomatosis With Polyangiitis
Intervention: Drug: Rituximab
7 Recruiting Determining Disease Activity Biomarkers in Individuals With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)
Conditions: Eosinophilic Granulomatosis With Polyangiitis;   Churg-Strauss Syndrome
8 Recruiting The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach
Conditions: Granulomatosis With Polyangiitis;   Wegener Granulomatosis;   Vasculitis
Interventions: Drug: 5 mg prednisone;   Drug: 0 mg prednisone
9 Recruiting Pediatric Vasculitis Initiative
Conditions: Wegeners Granulomatosis (Granulomatosis With Polyangiitis);   Microscopic Polyangiitis;   Churg Strauss Syndrome (Eosinophilic Granulomatosis With Polyangiitis);   Polyarteritis Nodosa;   Takayasu Arteritis;   Primary CNS Vasculitis;   Unclassified Vasculitis
10 Recruiting Vasculitis Pregnancy Registry
Conditions: Vasculitis;   Behcet's Disease;   CNS Vasculitis;   Cryoglobulinemic Vasculitis;   Eosinophilic Granulomatosis With Polyangiitis (EGPA);   Churg-Strauss Syndrome (CSS);   Granulomatosis With Polyangiitis (GPA);   Wegener's Granulomatosis;   IgA Vasculitis;   Henoch-Schoenlein Purpura (HSP);   Microscopic Polyangiitis (MPA);   Polyarteritis Nodosa (PAN);   Takayasu Arteritis (TAK);   Urticarial Vasculitis;   Systemic Vasculitis
Intervention: Other: Online questionnaires
11 Recruiting One-Time DNA Study for Vasculitis
Conditions: Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss);   Giant Cell Arteritis;   Granulomatosis With Polyangiitis (Wegener's);   Microscopic Polyangiitis;   Polyarteritis Nodosa;   Takayasu's Arteritis
12 Not yet recruiting Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis
Conditions: ANCA-associated Vasculitis;   Granulomatosis With Polyangiitis;   Microscopic Polyangiitis;   EosinphilicGranulomatosis With Polyangiitis
13 Recruiting The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach
Condition: Granulomatosis With Polyangiitis
Interventions: Drug: Prednisone 5 mg/day;   Drug: Prednisone 0 mg/day
14 Recruiting A Study Evaluating the Safety and Efficacy of Ristova (Rituximab) in Combination With Glucocorticoids in Patients With Wegener's Granulomatosis or Microscopic Polyangitis
Condition: Wegener's Granulomatosis, Microscopic Polyangiitis
Interventions: Drug: methylprednisolone;   Drug: prednisone;   Drug: rituximab [Ristova]
15 Unknown  Alemtuzumab for ANCA Associated Refractory Vasculitis
Conditions: Vasculitis;   Microscopic Polyangiitis;   Granulomatosis With Polyangiitis;   Wegener's
Intervention: Drug: Alemtuzumab
16 Unknown  Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)
Conditions: Wegener's Granulomatosis;   Vasculitis
Interventions: Drug: mycophenolate mofetil;   Drug: cyclophosphamide
17 Recruiting Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
Conditions: Granulomatosis With Polyangiitis;   Microscopic Polyangiitis
Interventions: Drug: Glucocorticoids;   Drug: Rituximab
18 Recruiting Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD)
Conditions: Pulmonary Healthy Controls;   Interstitial Lung Disease;   Idiopathic Pulmonary Fibrosis;   Non-specific Interstitial Pneumonia;   Sarcoidosis;   Granulomatosis With Polyangiitis (Wegener's Disease)
Interventions: Device: multiple breath washout tests;   Device: impulse oscillometry;   Device: body plethysmography
19 Recruiting Rituximab Vasculitis Maintenance Study
Conditions: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis;   Microscopic Polyangiitis;   Wegener Granulomatosis
Interventions: Biological: Rituximab;   Drug: Azathioprine
20 Recruiting Low-dose Glucocorticoid Vasculitis Induction Study
Conditions: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis;   Microscopic Polyangiitis;   Wegener Granulomatosis
Interventions: Drug: Rituximab;   Drug: Glucocorticoids

   Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results    Last Page
Indicates status has not been verified in more than two years